Sequential changes in serum triglyceride levels during adjuvant tamoxifen therapy in breast cancer patients and the effect of dose reduction.

摘要: Tamoxifen (TAM) and estrogen increase serum triglyceride (TG) levels, sometimes inducing severe hypertriglyceridemia possibly contributing to death. Decreasing the dose of in replacement therapy may minimize its adverse effects, including hypertriglyceridemia. The TG, total cholesterol, low-density-lipoprotein (LDL) cholesterol high-density-lipoprotein (HDL) were measured periodically 116 breast cancer patients on adjuvant TAM at a 10 mg twice daily. TG level was significantly increased 15 months after treatment, but magnitude clinically insignificant most (n = 102). If levels rose above 400 mg/dl, reduced once daily 14). lowered safer reduction 14 patients. other four had early onset beginning (within 6 months), their did not decrease satisfactorily reduction. Hence, they required antilipemic medication with or without discontinuing TAM. This study suggests that reducing from decreases marked occurs some during treatment.